Guardant Health price target raised to $52 from $47 at Scotiabank

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health wrapped up 2024 on a high note, delivering 31% year over year revenue growth for the year, with initial 2025 guidance calling for 15%-16% y/y revenue growth, the analyst tells investors in a research note. Guardant remains well-positioned to continue to deliver outsized top line growth over the next several years, while achieving profitability with cash on hand, Scotiabank says.